

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 567 201 A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93201611.6

(51) Int. Cl.5: A61K 9/32, A61K 9/52,
A61K 9/54

(22) Date of filing: 16.04.87

This application was filed on 07 - 06 - 1993 as a divisional application to the application mentioned under INID code 60.

(30) Priority: 30.04.86 GB 8610572

(71) Applicant: AKTIEBOLAGET HÄSSLE

S-431 83 Mölndal(SE)

(43) Date of publication of application:
27.10.93 Bulletin 93/43

(72) Inventor: Lövgren, Kurt

Viollinvägen 2D

S-435 44 Mölnlycke(SE)

Inventor: Pilbrant, Ake

Snödroppevägen 6

S-434 45 Kungsbacka(SE)

Inventor: Yasumura, Mitsuru

37, Matsuzono-cho 5 chome

Nishinomiya, Hyogo 662(JP)

Inventor: Morigaki, Satoshi

275-84, Nakanoma,

Yachiyo-cho

Taka-gun, Hyogo 677-01(JP)

Inventor: Oda, Minoru

304-24, Ohaza-Yuya

Nakatsu-shi, Ohita 871(JP)

Inventor: Ohishi, Naohiro

1342-1, Ohaza-Tarumi,

Shinyoshitomimura

Chikujo-gun, Fukuoka 871-09(JP)

(60) Publication number of the earlier application in accordance with Art.76 EPC: 0 496 437

(64) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(54) Vehicles for oral administration of a specific pharmaceutically active acid labile substance.

(57) Improvements in the vehicles for oral administration of pharmaceutically active acid labile substances prone to discolouration, containing omeprazole where the administration vehicle comprises a core containing the omeprazole together with an alkaline reacting compound or an alkaline salt of omeprazole optionally mixed with an alkaline reacting compound, adopting the form either of a number of small beads optionally forming a tablet or a tablet as such and comprising a coating made out of one or more inert reacting subcoating layers comprising tablet excipients which are soluble or rapidly disintegrating in water, or polymeric, water soluble, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the alkaline reacting core and an enteric outer coating layer.

The present invention is related to a new stable pharmaceutical preparation containing omeprazole for oral use, and to a method for the manufacture of such a preparation.

From e.g. EP-A1-0 005 129 omeprazole, 5-methoxy-2(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, a potent inhibitor of gastric acid secretion is known. Omeprazole shows a powerful inhibitory action against secretion of gastric juice (Lancet, Nov 27, 1982, p. 1223-1224) and can be used for the treatment of gastric and duodenal ulcers. Omeprazole is, however, susceptible to degradation/transformation in acid reacting and neutral media. The half-life of omeprazole in water solutions at pH-values less than four is shorter than ten minutes. Also at neutral pH-values the degradation reaction proceeds rapidly, e.g. at pH=7 the half-life of omeprazole is about 14 hours, while at higher pH-values the stability in solution is much better (Pilbrant and Cederberg, Scand. J. Gastroenterology 1985; 20 (suppl. 108) p. 113-120). The stability profile is similar in solid phase. The degradation of omeprazole is catalyzed by acidic reacting compounds and is stabilized in mixtures with alkaline reacting compounds. The stability of omeprazole is also affected by moisture and organic solvents.

From what is said about the stability properties of omeprazole, it is obvious that an oral dosage form of omeprazole must be protected from contact with the acid reacting gastric juice in order to reach the small intestine without degradation.

In human pharmacological studies it was found that the rate of release of omeprazole from a pharmaceutical dosage form can influence the total extent of absorption of omeprazole to the general circulation (Pilbrant and Cederberg, Scand. J. Gastroenterology 1985; 20 (suppl. 108) p. 113-120). A fully bioavailable dosage form of omeprazole must release the active drug rapidly in the proximal part of the gastrointestinal canal.

In order to obtain a pharmaceutical dosage form of omeprazole which prevents omeprazole from contact with acidic gastric juice, the cores must be enteric coated. Ordinary enteric coatings, however, are made of acidic compounds. If covered with such a conventional enteric coating, omeprazole rapidly decomposes by direct or indirect contact with it, with the result that the preparations become rapidly discolored and lose in omeprazole content with the passage of time.

In order to enhance the storage stability the cores which contain omeprazole must also contain alkaline reacting constituents. When such an alkaline core is enteric coated with an amount of a conventional enteric coating polymer such as, for example, cellulose acetate phthalate, that permits the dissolution of the coating and the active drug contained in the cores in the proximal part of the small intestine, it also will allow some diffusion of water of gastric juice through the enteric coating into the cores, during the time the dosage form resides in the stomach before it is emptied into the small intestine. The diffused water of gastric juice will dissolve parts of the core in the close proximity of the enteric coating layer and there form an alkaline solution inside the coated dosage form. The alkaline solution will interfere with the enteric coating and eventually dissolve it.

An enteric coated dosage form of omeprazole was reported by Pilbrant and Cederberg, in the above cited Scand. J. Gastroenterology 1985; 20 (suppl. 108) p. 113-120. The publication describes a conventional enteric coated dosage form and states that it has an acceptable storage stability - for clinical studies. It was later found that the stability of this dosage form was insufficient during long-term storage required for a marketed pharmaceutical dosage form.

If a conventional formulation of omeprazole is made, the stability is not satisfactory, particularly in resistance to humidity, and special moisture-proof packing has been adopted to minimize the troubles. However, this provides no satisfactory solution to the problems in today's drug distribution system, and also leads to increased costs. Under the circumstances, there has been a demand for the development of new enteric preparations of omeprazole with better stability.

In DE-A1-3046 559 a way to coat a dosage form is described. First the dosage form is coated with a water insoluble layer containing microcrystalline cellulose and then with a second enteric coating with the aim to achieve a dosage form which releases the active drug in the colon. This method of preparation will not give the desired release of omeprazole in the small intestine.

US-A-2 540 979 describes an enteric coated oral dosage form, where the enteric coating is combined with a second and/or first coating of a water insoluble "wax" layer. This method of preparation is not applicable on cores containing omeprazole since direct contact between substances such as cellulose acetate phthalate (CAP) and omeprazole causes degradation and discolouration of omeprazole.

DE-B2-23 36 218 describes a method to produce a dialysis membrane consisting of a mixture of one or more conventional enteric coating polymers and one or more insoluble cellulose derivatives. Such a membrane will not give a proper protection of omeprazole in gastric juice.

DE-A1-1 204 363 describes a three-layer coating procedure. The first layer is soluble in gastric juice but is insoluble in intestinal juice. The second is water soluble regardless of pH and the third layer is an enteric

coating. This preparation as well as the preparation described in DE-A1-1 617 615 result in a dosage form which is not dissolved in gastric juice and which only dissolves slowly in intestinal juice. Such preparations cannot be used for omeprazole, where a rapid release of the drug in the small intestine is needed.

DE-A1 12 04 363 describes coating with three layers to achieve release of a drug in the ileum, an aim 5 which is outside the scope of the present invention.

GB-A-1 485 676 describes a way to obtain a preparation, which effervesces in the small intestine, by enteric coating a core containing the active drug and an effervescent system such as a combination of carbonate and/or bicarbonate salt and a pharmaceutically acceptable acid. The formulation cannot be adopted for a pharmaceutical dosage form containing omeprazole, as the presence of an acid in contact 10 with omeprazole in the cores would give a result that omeprazole was degraded.

WO 85/03436 describes a pharmaceutical preparation, wherein cores containing active drugs mixed with for instance buffering components such as sodium dihydrogenphosphate with the aim of maintaining a constant pH and a constant rate of diffusion, are coated with a first coating which controls the diffusion. This formulation cannot be adopted for omeprazole where a rapid release in the small intestine is wanted. Direct 15 application of an enteric coating onto the cores would also adversely influence the storage stability of such dosage forms containing omeprazole.

EP-A-124 495 describes enteric coated granules without subcoating or powder that are filled into hard gelatine capsules or a solution that is filled into soft capsules.

The object of the present invention is to provide an enteric coated dosage form of omeprazole, which is 20 stable to discolouration and which is resistant to dissolution in acid media and which dissolves rapidly in neutral to alkaline media and which has a good stability during long-term storage. The new dosage form is characterized in the following way. Core material in the form of small beads or tablets containing omeprazole together with an alkaline reacting compound, or an alkaline salt of omeprazole optionally 25 together with an alkaline reacting compound, and on said core material one or more inert reacting subcoating layers comprising tablet excipients which are soluble or rapidly disintegrating in water, or polymeric, water soluble, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the alkaline reacting core and an outer layer, which is an enteric coating. This/these inner layer/layers separates/separate the alkaline core material from the outer layer, which is an enteric coating. The final, enteric coated dosage form is treated in a suitable way to reduce the water content to a very low 30 level in order to obtain a good stability of the dosage form during long-term storage.

Detailed description of the invention

Cores

35 Omeprazole is mixed with inert, preferably water soluble, conventional pharmaceutical constituents to obtain the preferred concentration of omeprazole in the final mixture and with an alkaline reacting, otherwise inert, pharmaceutically acceptable substance (or substances), which creates a "micro-pH" around each omeprazole particle of not less than pH=7, preferably not less than pH=8, when water is adsorbed to the 40 particles of the mixture or when water is added in small amounts to the mixture. Such substances can be chosen among, but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$, $(\text{Mg}_6\text{Al}_2(\text{OH})_{16}\text{CO}_3 \cdot 4\text{H}_2\text{O})$, $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$ or similar compounds; organic pH-buffering substances such as trihydroxymethylaminomethane or other similar, pharmaceutically acceptable pH-buffering substances. The stabilizing, high pH-value in the powder mixture can also be achieved by using an alkaline reacting salt of 45 omeprazole such as the sodium, potassium, magnesium, calcium etc. salts of omeprazole, which are described in e.g. EP-A2-124 495, either alone or in combination with a conventional buffering substance as previously described.

50 The powder mixture is then formulated into small beads i.e. pellets, or tablets, by conventional pharmaceutical procedures. The pellets or tablets are used as cores for further processing.

Separating layer

55 The omeprazole containing alkaline reacting cores must be separated from the enteric coating polymer(s) containing free carboxyl groups, which otherwise causes degradation/discolouration of omeprazole during the coating process or during storage. The subcoating layer, in the following defined as the

separating layer, also serves as a pH-buffering zone in which hydrogen ions diffusing from the outside in towards the alkaline core can react with hydroxyl ions diffusing from the alkaline core towards the surface of the coated articles. The pH-buffering properties of the separating layer can be further strengthened by introducing in the layer substances chosen from a group of compounds usually used in antacid formulations such as, for instance, magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$, $(\text{Mg}_2\text{Al}_2(\text{OH})_6\text{CO}_3 \cdot 4\text{H}_2\text{O})$, $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$ or similar compounds; or other pharmaceutically acceptable pH-buffering compounds such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, citric or other suitable, weak, inorganic or organic acids.

The separating layer consists of one or more water soluble inert layer, optionally containing pH-buffering compounds.

The separating layer(s) can be applied to the cores - pellets or tablets - by conventional coating procedures in a suitable coating pan or in a fluidized bed apparatus using water and/or conventional organic solvents for the coating solution. The material for the separating layer is chosen among the pharmaceutically acceptable, water soluble, inert compounds or polymers used for film-coating applications such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, methylcellulose, hydroxymethyl cellulose, hydroxypropyl methylcellulose or polyvinyl acetal diethylaminoacetate. The thickness of the separating layer is not less than 2 μm , for small spherical pellets preferably not less than 4 μm , for tablets preferably not less than 10 μm .

In the case of tablets another method to apply the coating can be performed by the drycoating technique. First a tablet containing omeprazole is compressed as described above. Around this tablet a layer is compressed using a suitable tableting machine. The outer, separating layer, consists of pharmaceutically acceptable, in water soluble or in water rapidly disintegrating tablet excipients. The separating layer has a thickness of not less than 1 mm. Ordinary plasticizers colorants, pigments, titanium dioxide, talc and other additives may also be included into the separating layer.

Enteric coating layer

The enteric layer coating layer is applied on to the subcoated cores by conventional coating techniques such as, for instance, pan coating or fluidized bed coating using solutions or polymers in water and/or suitable organic solvents or by using latex suspensions on said polymers. As enteric coating polymers can be used, for example, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters such as, for instance, compounds known under the trade name Eudragit® L 12,5 or Eudragit® L 100 (Röhm Pharma), or similar compounds used to obtain enteric coatings. The enteric coating can also be applied using water-based polymer dispersions, e.g. Aquateric® (FMC Corporation), Eudragit® L100-55 (Röhm Pharma), Coating CE 5142 (BASF). The enteric coating layer can optionally contain a pharmaceutically acceptable plasticizer such as, for instance, cetanol, triacetin, citric acid esters such as, for instance, those known under the trade name Citroflex® (Pfizer), phthalic acid esters, dibutyl succinate or similar plasticizers. The amount of plasticizer is usually optimized for each enteric coating polymer(s) and is usually in the range of 1-20 % of the enteric coating polymer(s). Dispersants such as talc, colorants and pigments may also be included into the enteric coating layer.

Thus, the special preparation according to the invention consists of cores containing omeprazole mixed with an alkaline reacting compound or cores containing an alkaline salt of omeprazole optionally mixed with an alkaline reacting compound. The alkaline reacting core material and/or alkaline salt of the active ingredient, omeprazole, enhance the stability of omeprazole. The cores suspended in water forms a solution or a suspension which has a pH, which is higher than that of a solution in which the polymer used for enteric coating is just soluble. The cores are coated with an inert reacting water soluble or in water rapidly disintegrating coating, optionally containing a pH-buffering substance, which separates the alkaline cores from the enteric coating. Without this separating layer the resistance towards gastric juice would be too short and/or the storage stability of the dosage form would be unacceptably short. The sub-coated dosage form is finally coated with an enteric coating rendering the dosage form insoluble in acid media, but rapidly disintegrating/dissolving in neutral to alkaline media such as, for instance the liquids present in the proximal part of the small intestine, the site where dissolution is wanted.

Final dosage form

The final dosage form is either an enteric coated tablet or capsule or in the case of enteric coated pellets, pellets dispensed in hard gelatin capsules or sachets or pellets formulated into tablets. It is essential for the long term stability during storage that the water content of the final dosage form containing omeprazole (enteric coated tablets, capsules or pellets) is kept low, preferably not more than 1.5 % by weight. As a consequence the final package containing hard gelatin capsules filled with enteric coated pellets preferably also contain a desiccant, which reduces the water content of the gelatin shell to a level where the water content of the enteric coated pellets filled in the capsules does not exceed 1.5 % by weight.

Process

A process for the manufacture of the oral dosage form represents a further aspect of the invention. After the forming of the cores the cores are first coated with the separating layer and then with the enteric coating layer. The coating is carried out as described above.

The preparation according to the invention is especially advantageous in reducing gastric acid secretion and/or providing a gastrointestinal cytoprotective effect. It is administered one to several times a day. The typical daily dose of the active substance varies and will depend on various factors such as the individual requirements of the patients, the mode of administration and disease. In general the daily dose will be in the range of 1-400 mg of omeprazole.

The invention is described in detail in the following examples:

EXAMPLES

25

Example 1

The effect of different magnesium compounds was evaluated in the form of enteric coated tablets. Tablet cores were first made by known techniques according to the formulations listed in Table 1, followed by application of separating layers and enteric coating layers shown in Table 2.

Table 1

Formulations No.	Formulations for the tablet cores (mg)						
	1	2	3	4	5	6	7
Omeprazol	15.0	15.0	15.0	15.0	15.0	15.0	15.0
Lactose	134.0	119.0	119.0	119.0	118.8	118.5	119.0
Hydroxypropyl cellulose (low substitution)	5.0	5.0	5.0	5.0	5.0	5.0	5.0
Hydroxypropyl cellulose	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Talc	5.0	5.0	5.0	5.0	5.0	5.0	5.0
Na ₂ HPO ₄	-	15.0	-	-	0.2	-	-
Na lauryl sulfate	-	-	-	-	-	0.5	-
MgO	-	-	15.0	-	-	-	-
Mg(OH) ₂	-	-	-	15.0	15.0	15.0	-
Synthetic hydrotalcite [Al ₂ O ₃ .6MgO.CO ₂ .12H ₂ O]	-	-	-	-	-	-	15.0
Total	160.0	160.0	160.0	160.0	160.0	160.0	160.0

50

55

Table 2 Formulations for coatings (mg)

5 Formulation No.	I	II	III	IV
Separating layer (inner):				
10 Hydroxypropyl cellulose	-	2.0	2.0	2.0
Magnesium hydroxide	-	-	0.3	-
Synthetic hydrotalcite	-	-	-	0.3
Separating layer (outer):				
15 Hydroxypropyl cellulose	-	2.0	2.0	2.0
Enteric coating layer:				
20 Hydroxypropyl methylcellulose				
phthalate	7.0	7.0	7.0	7.0
Cetyl alcohol	0.5	0.5	0.5	0.5

30 The tablets thus obtained were stored in open form under so called accelerated conditions, that is 40°C, and 75 % relative humidity, and the changes in appearance with the passage of time were observed. Storage for six months under these conditions corresponds to storage at normal temperature for three years. This means that high stability sufficient for practical use may be assured if a drug remains intact for about one week under the mentioned conditions. The result is summarized in Table 3. As may be seen from the table, a remarkable stabilizing effect is achieved when a magnesium compound is contained in the inner layer.

40

45

50

55

Table 3

Stabilizing Effect (Appearance of Preparations)								
	Coating Layer	Core material						
		1	2	3	4	5	6	7
5	I	At the start 60 °C; after 7 days 40 °C; 75% RH; after 7 days	C E F	A D E	A C B	A C B	A C B	A D E
10	II	At the start 60 °C; after 7 days 40 °C; 75% RH; after 7 days	A E E	A B D	A A A	A A A	A A A	A C D
15	III	At the start 60 °C; after 15 days 40 °C; after 30 days 40 °C; 75% after 15 days	A B A B	A A A A	A A A A	A A A A	A A A A	A A A A
20	IV	At the start 60 °C; after 15 days 40 °C; after 30 days 40 °C; 75% RH; after 15 days	A B A B	A A A A	A A A A	A A A A	A A A A	A A A A

A: white, B: brownish white, C: faint brown, D: light brown, E: brown, F: deep brown.

25 All the samples evaluated as A (white) in the above table showed no discoloration even on split surfaces. The samples evaluated as B (brownish white) showed little change in appearance, but some discoloration was observed on split surfaces. Table 4 shows the result of a stability test on the omeprazole preparation according to Example 1 (Formulation No 4-IV). The formulation was stored in a closed glass bottle at room temperature for the indicated period of time. This clearly demonstrates that preparations with unusually high stability were obtained.

Table 4

35 Stability of enteric coated omeprazole preparations (Tablets of Formulation No.4-IV)		
Storage Period	Appearance	Omeprazole Content(%)
40 At the start of test	White	100.0
1 year at room temp.	White	99.9
2 years at room temp.	White	100.0

45

50

55

Example 2Uncoated pellets

5

10

I

Mannitol powder	16	150 g
Lactose anhydrous		800 g
Hydroxypropyl cellulose		600 g
Microcrystalline cellulose		400 g

15

II

Omeprazole	2	000 g
Sodium lauryl sulphate		50 g
Disodium hydrogen phosphate		80 g
Distilled water		4 400 g

20

The dry ingredients (I) were premixed in a mixer. Addition of a granulation liquid (II) containing suspended omeprazole was made and the mass was wet-mixed to a proper consistency. The wet mass was pressed through an extruder and spheronized to pellets. The pellets were dried and classified into suitable particle size ranges.

30

Subcoated pellets

35

III

Uncoated omeprazole pellets	6	000 g
Hydroxypropyl methylcellulose		240 g
Distilled water		4 800 g

40 The polymer solution (III) was sprayed on the uncoated pellets in a fluidized bed apparatus. The spray guns were placed above the fluidized bed.

45

50

55

Enteric-coated pellets

5	Subcoated pellets	500 g
IV	Hydroxypropyl methylcellulose phthalate Cetyl alcohol Acetone Ethanol	57 g 3 g 540 g 231 g
10		

15 The polymer solution (IV) was sprayed on the subcoated pellets in a fluidized bed apparatus with spray guns placed above the bed. After drying to a water content of 0.5 % the enteric coated pellets were classified and filled into hard gelatin capsules in an amount of 225 mg, corresponding to 20 mg of omeprazole. 30 capsules were packed in tight containers together with a desiccant.

20 **Example 3**

This example illustrates that a variety of polymers can be used for subcoating, e.g. hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohols.

25 Uncoated pellets

30	I	Mannitol powder	1 620 g
		Lactose anhydrous	80 g
		Hydroxypropyl cellulose	60 g
		Microcrystalline cellulose	40 g
35			
40	II	Omeprazole	200 g
		Sodium lauryl sulphate	1.0 g
		Disodium hydrogen phosphate	9.3 g
		Distilled water	515 g

45 The uncoated pellets were prepared as described in Example 2.

Subcoated pellets

50	III	Uncoated omeprazole pellets	500 g
		Polyvinylpyrrolidone	20 g
		Ethanol	400 g

55 The subcoated pellets were prepared as described in Example 2.

Enteric-coated pellets

5	Subcoated pellets	500 g	
10	IV	Hydroxypropyl methyl-cellulose phthalate	45 g
15		Cetyl alcohol	5 g
20		Acetone	219 g
25		Ethanol	680 g

15 The enteric-coated pellets were prepared as described in Example 2.

Example 4Uncoated pellets

25	I	Mannitol powder	1 610 g
30	II	Lactose anhydrous	80 g
35		Hydroxypropyl cellulose	60 g
40		Microcrystalline cellulose	40 g
45		Omeprazole	200 g
50		Pluronic® F68	10 g
55		Disodium hydrogen phosphate	24 g
60		Distilled water	450 g

40 The uncoated pellets were prepared as described in Example 2.

Subcoated pellets

45	III	Uncoated pellets	500 g
50		Polyvinylpyrrolidone	30 g
55		Ethanol	400 g

The subcoated pellets were prepared as described in Example 2.

Enteric coated pellets

5	Subcoated pellets	500 g
IV	Hydroxypropyl methyl-cellulose phthalate Cetyl alcohol Methylene chloride Ethanol	45 g
10		5 g
		371 g
		680 g

15 The enteric coated pellets were prepared as described in Example 2.

Example 5

20 This example illustrates that a variety of polymers can be used as enteric coating material e.g. cellulose acetate phthalate, poly-(vinyl acetate/vinyl alcohol phthalate), hydroxypropyl methyl cellulose phthalate, poly-(methacrylic acid/methacrylic acid methyl esters), poly-(acrylic acid/methacrylic acid methyl esters). The polymers can be applied with/without plasticizer, e.g. polyethylene glycols, triacetin, dimethyl polysiloxan, Citroflex®, cetyl alcohol, stearyl alcohol, diethyl phthalate.

25 Enteric-coated pellets can also be manufactured from water-based polymer dispersions, e.g. Aquateric®(FMC Corporation), Eudragit®L 100-55, Coating CE 5142 (BASF).

Uncoated pellets

30	I	Lactose powder Lactose anhydrous Hydroxypropyl cellulose Colloidal silica	277 g 118 g 25 g 25 g
35	Omeprazole Sodium lauryl sulphate Disodium hydrogen phosphate Sodium dihydrogen phosphate Distilled water	50 g	
		5 g	
		2 g	
		0.1 g	
		170 g	

45 The uncoated pellets were prepared as described above.

Subcoated pellets

50 The uncoated pellets were subcoated as described in Example 2.

Enteric coated pellets

5	Subcoated pellets	500 g
	Eudragit®L 500	45 g
10	III { Stearyl alcohol	4.5 g
	Ethanol	1 320 g

The enteric coated pellets were prepared as described above.

15 Example 6

Formulations with the sodium salt of omeprazole.

20 Uncoated pellets

25	I { Omeprazole sodium salt	339 g
	Mannitol powder	2 422 g
	Lactose anhydrous	120 g
	Hydroxypropyl cellulose	90 g
	Microcrystalline cellulose	60 g
30	II { Sodium lauryl sulphate	7 g
	Distilled water	650 g

35 The preparation was made as described in Example 2 with the exception that the omeprazole sodium salt was added together with the other ingredients in mixture I.

40

45

50

55

Subcoated pellets

5	Uncoated pellets	500 g
	Hydroxypropyl methylcellulose	20 g
10	Aluminium hydroxide/magnesium carbonate	4 g
	Distilled water	400 g

15	Pellets subcoated with III	500 g
IV	Hydroxypropyl methylcellulose	20 g
20	Distilled water	400 g

The two subcoat layers, III and IV, were applied to the uncoated pellets in a fluidized bed apparatus in consecutive order as previously described.

Enteric coated pellets

30	Subcoated pellets	500 g
	Hydroxypropyl methylcellulose	
35	phthalate	57 g
	Cetyl alcohol	3 g
	Acetone	540 g
	Ethanol	231 g

40

The preparation of enteric coated pellets was performed as described in Example 2.

Examples 7 and 8

45

Formulations with the magnesium salt of omeprazole.

50

55

Uncoated pellets

			Example No
			7 8
5	I	Omeprazole magnesium salt	222 g 222 g
10		Mannitol powder	1 673 g 1 473 g
15		Microcrystalline cellulose	100 g 100 g
20		Magnesium hydroxide	- 200 g
25	II	Sodium lauryl sulphate	5 g 5 g
30		Distilled water	500 g 375 g

20 The preparation was made as described in Example 2 with the exception that the omeprazole salt was added together with the other ingredients in mixture I.

Subcoated pellets

		Examples
		<u>7 and 8</u>
30	Uncoated pellets	500 g
35	III	Hydroxypropyl methylcellulose
		20 g
		Distilled water 400 g

40 The pellets were prepared as described in Example 2.

45

50

55

Enteric coated pellets

5

Examples7 and 8

10

Subcoated pellets

Hydroxypropyl methyl-cellulose phthalate

Cetyl alcohol

Acetone

Ethanol

500 g

57 g

3 g

540 g

231 g

15

20

Examples 9 and 10

Manufacture of tablets.

25 Tablet cores

30

Examples No9 10

35

I Omeprazole

Omeprazole sodium salt, corresponding to omeprazole 400 g

Lactose, anhydrous

Polyvinylpyrrolidone, crosslinked

Sodium carbonate, anhydrous

400 g -

- 426 g

1 420 g 1 406 g

100 g 100 g

15 g -

40

Methyl cellulose

Distilled water

12 g 12 g

200 g 200 g

45

Magnesium stearate

30 g 30 g

50

The powder mixture I was carefully homogenized and granulated by the solution II. The wet mass was dried in a fluidized bed dryer using an inlet air temperature of +50 °C for 30 minutes. The dried mixture was then forced through a sieve with an aperture of 0.5 mm. After mixing with magnesium stearate the granulate was tabletted on a tabletting machine using 6 mm punches. The tablet weight was 100 mg.

Subcoating

The tablets containing omeprazole were subcoated with approximately 10 % by weight of hydroxypropyl methylcellulose from a water solution using a perforated coating pan apparatus.

5 The tablets containing omeprazole sodium salt were subcoated using the dry coating technique. A tablet granulate containing

10	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px;">Lactose anhydrous</td><td style="padding: 2px; text-align: right;">4 000 g</td></tr> <tr> <td style="padding: 2px;">Polyvinylpyrrolidone, (PVP)</td><td style="padding: 2px; text-align: right;">180 g</td></tr> <tr> <td style="padding: 2px;">Ethanol 95 %</td><td style="padding: 2px; text-align: right;">420 g</td></tr> <tr> <td style="padding: 2px;">Magnesium stearate</td><td style="padding: 2px; text-align: right;">42 g</td></tr> </table>	Lactose anhydrous	4 000 g	Polyvinylpyrrolidone, (PVP)	180 g	Ethanol 95 %	420 g	Magnesium stearate	42 g
Lactose anhydrous	4 000 g								
Polyvinylpyrrolidone, (PVP)	180 g								
Ethanol 95 %	420 g								
Magnesium stearate	42 g								

was prepared in the following way. The lactose was granulated with a solution of PVP in ethanol and dried.

15 After drying magnesium stearate was admixed.

The granulate mass was dry coated around the tablet cores of Example 9 using a Manesty Dry Cota® tableting machine. The tablet weight of the dry coated tablets was 475 mg. Each tablet contained 20 mg of omeprazole.

Enteric coating

The subcoated tablets obtained above were enteric coated using the same coating solution:

25	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px;">Hydroxypropyl methylcellulose phthalate</td><td style="padding: 2px; text-align: right;">1 500 g</td></tr> <tr> <td style="padding: 2px;">Cetyl alcohol</td><td style="padding: 2px; text-align: right;">105 g</td></tr> <tr> <td style="padding: 2px;">Methylene chloride</td><td style="padding: 2px; text-align: right;">15 000 g</td></tr> <tr> <td style="padding: 2px;">Isopropanol</td><td style="padding: 2px; text-align: right;">15 000 g</td></tr> <tr> <td style="padding: 2px;">Distilled water</td><td style="padding: 2px; text-align: right;">3 150 g</td></tr> </table>	Hydroxypropyl methylcellulose phthalate	1 500 g	Cetyl alcohol	105 g	Methylene chloride	15 000 g	Isopropanol	15 000 g	Distilled water	3 150 g
Hydroxypropyl methylcellulose phthalate	1 500 g										
Cetyl alcohol	105 g										
Methylene chloride	15 000 g										
Isopropanol	15 000 g										
Distilled water	3 150 g										

30 The coating was applied in a perforated coating pan apparatus. An approximate amount of one kg of coating solution was applied for each kg of tablets.

COMPARATIVE EXAMPLES

35

Examples I, II and III

These examples illustrate that the buffer salt used effects the enteric-coated omeprazole pellets properties when the sub-coating layer is absent. A high amount of buffer salt is needed in order to obtain a long shelf life for the product. At the same time this type of pellets shows inferior acid resistance properties. C.f. also the Example 4 above.

45

50

55

Uncoated pellets

5	Examples No		
	<u>I</u>	<u>II</u>	<u>III</u>
10	I	Mannitol powder	1 610 g
		Lactose anhydrous	1 610 g
		Hydroxypropyl cellulose	60 g
		Microcrystalline cellulose	40 g
			60 g
15	II	Omeprazole	200 g
		Pluronic®F68	10 g
		Disodium hydrogen phosphate	2 g
		Distilled water	450 g
			200 g
20	III	10 g	10 g
		24 g	450 g
			450 g
25			
30			

The uncoated pellets were prepared as described in Example 2 above.

Enteric coated pellets

35	Uncoated pellets		500 g
40	III	Hydroxypropyl methyl-	
		cellulose phthalate	45 g
		Cetyl alcohol	5 g
		Methylene chloride	371 g
		Ethanol	680 g

The coated pellets were prepared as described in Example 2 above.

Example IV

This formulation is the same as in Example 6 above, but no subcoating layer was used.

Uncoated pellets

5	I	Omeprazole sodium salt	339 g
		Mannitol powder	2 422 g
10		Lactose anhydrous	120 g
		Hydroxypropyl cellulose	90 g
10		Microcrystalline cellulose	60 g
15	II	Sodium lauryl sulphate	7 g
		Distilled water	, 650 g

The preparation was made as described in Example 6.

Enteric-coated pellets

25		Uncoated pellets	500 g
	III	Hydroxypropyl methylcellulose	
		phthalate	57 g
30		Cetyl alcohol	3 g
		Acetone	540 g
		Ethanol	231 g

35 The enteric coated pellets were prepared as described in Example 2.

Example V

40 This formulation is the same as in Example 8 above, but no subcoating layer was used.

Uncoated pellets

45	I	Omeprazole magnesium salt	222 g
		Mannitol powder	1 473 g
		Microcrystalline cellulose	100 g
50		Magnesium hydroxide	200 g
55	II	Sodium lauryl sulphate	5 g
		Distilled water	375 g

65 The preparation was made as described in Example 8.

Enteric coated pellets

5	Uncoated pellets	500 g
10 III	Hydroxypropyl methylcellulose	57 g
	phthalate	3 g
	Cetyl alcohol	540 g
	Acetone	231 g
	Ethanol	

15 The pellets were prepared as described in Example 2 above.

Properties of the enteric coated pellets

20 For the preparations according to Examples 2-8 and comparative Examples I-V above one or both of the following studies have been performed.

Acid resistance

25 The following resistance of the formulations was studied in the following way: The formulations were added to gastric fluid USP (without enzyme), 37 °C (paddle) 100 r/min. After 2 hours the actual amount of omeprazole remaining intact in the formulations was determined.

Rate of dissolution in buffer solution

30 In order to establish the rate of dissolution in the small intestine the formulations were added to a buffer solution. Buffer solution 37 °C, USP dissolution apparatus No 2 (paddle), 100 r/min. After 10 or 30 minutes the amount of omeprazole dissolved was determined. The results are presented in the following Table 5.

35

40

45

50

55

Table 5

Example No.	Omeprazole content mg/g	Acid resistance amount intact omeprazole (%) after 2 hours	% dissolved omeprazole at different pH:s and after 10 or 30 min		
			%	pH	min
2	89.2	96	100	6.8	10
3	90	96	91	6.0	10
4	88	89	7)		
5	82	93	70	7.5	30
6	81.3	87	93	6.8	10
7	91	95	"		
8	89	98	"		
I	93	97	"		
II	92	94	"		
III	94	58	"		
IV	86.5	4	"		
V	91	93	"		

¹⁾ The stability of the formulation was studied during storage in glass bottles also containing a desiccant device. After one month storage at +50 °C the formulation according to Example 4 was virtually intact with no change in appearance or physicochemical characteristics. Pellets according to Examples I and II turned brown due to degradation, while the pellets according to Example III retained to original white colour.

^{"")} The formulations according to Examples 7 and 8 were white and not affected by the coating process. The enteric coated pellets according to Example V, where the enteric coating was applied directly on the cores according to Example 8, was discoloured already during the enteric coating process.

Further comparative test

5 This example demonstrates the effect of the moisture content of the preparations according to the invention on storage stability.

The stability of omeprazole pellets according to the invention was compared with that of omeprazole pellets with higher water content. Omeprazole pellets were prepared according to the invention with a water content of 1 %. Two other portions of the same formulation were conditioned to a water content of 2 % and 10 5 % respectively. The three formulations, packed in tight containers not containing a desiccant, were stored for one month at + 50 °C. After this time the packages were opened and the pellets were assayed for the amount of omeprazole by HPLC. The formulation according to the invention had an omeprazole content of 98.5 % of the initial value. The other two formulations with at water content of 2 and 5 % respectively were totally degraded and had only trace amounts of intact omeprazole.

15

DISCUSSION

From the results given in Table 5 it can be seen that formulations containing omeprazole with acceptable acid resistance can be prepared by using a conventional enteric coating technique (see for 20 instance Examples I, II and V). However, it is also obvious that the storage stability of the formulations according to Examples I, II and V is not acceptable, since a discolouration, showing a degradation of omeprazole, occurs during short storage at an elevated storage temperature (Examples I and II) or already during the enteric coating process (Example V).

If the amount of alkaline substances in the cores is increased to a level where omeprazole has an acceptable storage stability (Example III) or if an alkaline reacting salt of omeprazole is used in the preparation of the cores (Example IV), then, without the separating layer of the invention, the resistance to dissolution in acid media becomes unacceptably low and much or all of the active substance will degrade already in the stomach and thus, it has no effect on the gastric acid secretion.

When the preparation is carried out to the invention as for instance in Example 4, a good resistance 30 towards gastric juice as well as a good stability during long-term storage is obtained. This is in contrast with the formulations in Examples I, II and III where either an acceptable acid resistance or an acceptable storage stability can be achieved - but not both. The same comparison can be made between the formulations according to Examples 7 and 8 according to the invention and the formulation according to Example V, where the separating layer was omitted. Examples 7 and 8 differ in that a buffering substance, 35 magnesium hydroxide, has been included in the cores of Example 8. This further improves the acid resistance as well as the storage stability of Example 8 in comparison with Example 7.

The further comparative test shows the great importance of a low water content in the preparations.

Thus, in order to prepare pharmaceutical formulations of omeprazole for oral use, which exert good 40 stability during long-term storage as well as good stability during the residence in the stomach after administration, the preparation is made in the following way:

- a) Omeprazole together with an alkaline reacting compound or compounds or an alkaline reacting salt of omeprazole optionally mixed with alkaline reacting compound are included in the core material.
- b) The core material is subcoated with one or more inert, in water soluble or in water rapidly 45 disintegrating layers, which separate the alkaline reacting core from the enteric coating. The subcoating layer may optionally contain pH-buffering compounds.
- c) The subcoated cores are coated with an acid insoluble enteric coating, optionally containing plasticizers.

Biopharmaceutical studies

50

The hard gelatin capsules according to Example 2 were administered to 12 healthy, young male volunteers in the following way:

The volunteers came to the laboratory in the morning after having abstained from food since 10 p.m. the night preceding the experimental day. A zero time blood sample was taken. One omeprazole capsule 55 according to Example 2 was administered together with 150 ml of tap water. Further blood samples were taken during the day.

In another experiment the same volunteers were administered 20 mg of omeprazole in the form of a suspension of micronized omeprazole in a sodium bicarbonate water solution. In order to reduce the

degradation of omeprazole in the stomach to a minimum, solid bicarbonate solution was given to the subjects just before the administration of the omeprazole suspension and at further four times with a 10-minutes interval after the drug intake. The concentration of omeprazole in blood plasma was assayed by high pressure liquid chromatography (Persson, Lagerström and Grundevik. Scand J Gastroenterol 1985, 20, 5 (suppl 108), 71-77. The mean plasma concentrations are given in Table 6.

Table 6

The plasma concentrations ($\mu\text{mol/l}$) after 20 mg single oral doses of omeprazole given as hard gelatin capsules according to Example 2 and as a suspension of micronized omeprazole in sodium bicarbonate solution.

Time (min)	Capsules	Suspension
10		0.84
20		0.90
25	0.03	0.84
30		0.64
45		0.44
60	0.22	0.24
90	0.36	
30	0.39	0.13
120		
150	0.29	
180	0.20	0.04
35	0.10	
210		
240	0.05	0.01
300	0.02	0
40		
360	0.01	
420	0	

45 Although the plasma concentration peak at different times, the two formulations are bioequivalent. The mean relative bioavailability of the capsules in comparison with the suspension was 85 % +23 % (S.D.). The comparison was based on the total area under individual plasma concentration versus times curves.

Thus, by preparing capsules according to the invention it is possible to obtain a preparation with the same bioavailability as a suspension containing the same amount to micronized active compound. It is, 50 however, to be noticed that when the suspension is administered, the patients must also be given sodium bicarbonate solution frequently in order to minimize pre-absorption degradation of omeprazole in the stomach.

Claims

55 1. Improvements in the vehicles for oral administration of pharmaceutically active acid labile substances prone to discolouration, containing omeprazole characterized in that the administration vehicle comprises a core containing the omeprazole together with an alkaline reacting compound or an alkaline salt

of omeprazole optionally mixed with an alkaline reacting compound, adopting the form either of a number of small beads optionally forming a tablet or a tablet as such and comprising a coating made out of one or more inert reacting subcoating layers comprising tablet excipients which are soluble or rapidly disintegrating in water, or polymeric, water soluble, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the alkaline reacting core and an enteric outer coating layer.

- 5 2. Improvements according to claim 1, wherein the subcoating of the core containing omeprazole comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose or polyvinyl-pyrrolidone.
- 10 3. Improvements according to claim 1 wherein the applied subcoating comprises two or more sub-layers and where the inner sub-layer contains one or more of magnesium oxide, magnesium hydroxide or composite substance $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$ or $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$, wherein n not is an integer and less than two.
- 15 4. Improvements according to claim 1 wherein the omeprazole containing core comprises omeprazole mixed with a pH-buffering alkaline compound rendering to the microenvironment of the omeprazole a pH of 7-12.
- 20 5. Improvements according to claim 4 wherein the alkaline compound which the omeprazole is mixed with comprises one or more magnesium oxide, hydroxide or carbonate, aluminium, calcium, sodium or potassium carbonate, phosphate or citrate, the composite aluminium/magnesium compounds $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$ or $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$, wherein n not is an integer and less than two.
- 25 6. Improvements according to claim 4 wherein the alkaline core comprises an alkaline salt of omeprazole such as the sodium, potassium, magnesium, calcium or ammonium salt.
7. Improvements according to claim 4 wherein the alkaline core comprises an alkaline salt of omeprazole mixed with an otherwise alkaline compound.
- 30 8. Improvements according to claim 1 wherein the enteric outer coating comprises hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, co-polymerized methacrylic acid/methacrylic acid methyl ester or polyvinyl acetate phthalate, optionally containing a plasticizer.
- 35 9. Improvements according to claim 1 wherein the dosage form containing the administration vehicle with omeprazole has a water contents which does not exceed 1,5% by weight.

40

45

50

55

EP 0 567 201 A3



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 567 201 A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93201611.6

(51) Int. Cl.⁶: **A61K 9/32, A61K 9/52,
A61K 9/54**

(22) Date of filing: **16.04.87**

(23) Priority: **30.04.86 GB 8610572**

(24) Date of publication of application:
27.10.93 Bulletin 93/43

(25) Publication number of the earlier application in
accordance with Art.76 EPC: **0 496 437**

(26) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(27) Date of deferred publication of the search report:
07.06.95 Bulletin 95/23

(28) Applicant: **AKTIEBOLAGET HÄSSLE**

S-431 83 Mölndal (SE)

(29) Inventor: **Lövgren, Kurt**

Violinvägen 2D

S-435 44 Mölnlycke (SE)

Inventor: **Pilbrant, Åke**

Snödroppevägen 6

S-434 45 Kungsbacka (SE)

Inventor: **Yasumura, Mitsuru**
37, Matsuzono-cho 5 chome

Nishinomiya,

Hyogo 662 (JP)

Inventor: **Morigaki, Satoshi**

275-84, Nakanoma,

Yachiyō-cho

Taka-gun,

Hyogo 677-01 (JP)

Inventor: **Oda, Minoru**

304-24, Ohaza-Yuya

Nakatsu-shi,

Ohita 871 (JP)

Inventor: **Ohishi, Naohiro**

1342-1, Ohaza-Tarumi,

Shinyoshitomimura

Chikujo-gun,

Fukuoka 871-09 (JP)

(74) Representative: **Linderoth, Margareta et al**
AB Astra
Patent Department
S-151 85 Södertälje (SE)

(54) Vehicles for oral administration of a specific pharmaceutically active acid labile substance.

(57) Improvements in the vehicles for oral administration of pharmaceutically active acid labile substances prone to discolouration, containing omeprazole where the administration vehicle comprises a core containing the omeprazole together with an alkaline reacting compound or an alkaline salt of omeprazole optionally mixed with an alkaline reacting compound, adopting the form either of a number of small beads optionally forming a tablet or a tablet as such and comprising a coating made out of one or more inert reacting subcoating layers comprising tablet excipients which are soluble or rapidly disintegrating in water, or polymeric, water soluble, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the alkaline reacting core and an enteric outer coating layer.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 20 1611

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages		
D,X	EP-A-0 124 495 (AKTIEBOLAGET HÄSSLE) * page 1 - page 3, line 11 * * page 6, line 6 - line 35; example 12 * * page 13, line 25 - page 14, line 17; claims 1,8 *	1,2,6,8, 9	A61K9/32 A61K9/52 A61K9/54
Y	---	4,5,7	
D,Y	EP-A-0 173 664 (AKTIEBOLAGET HÄSSLE) * page 2, line 1 - page 3, line 26 * * page 21, line 26 - page 22, line 8 * * page 27, line 1 - line 20 * * page 37, line 19 - page 38, line 12 *	4,5,7	
D,A	EP-A-0 080 602 (BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH) * page 2, line 1 - line 21 * * page 3, line 6 - line 13 * * page 17, line 10 - line 20 * * page 18, line 1 - line 20 * * page 20, line 14 - line 22 *	1-9	
A	GB-A-760 403 (ABBOT LABORATORIES) * page 1, line 11 - line 34 * * page 2, line 31 - line 70 * * page 6, line 3 - line 18 *	1-9	TECHNICAL FIELDS SEARCHED (Int.Cl.) A61K
A	DE-A-32 33 764 (R.P.SCHERER) * page 6, line 7 - page 7, paragraph 3 * * page 8, last paragraph - page 9, line 1 *	1-9	
A	PATENT ABSTRACTS OF JAPAN vol. 8 no. 106 (C-223) [1543] ,18 May 1984 & JP-A-59 020219 (SHINETSU KAGAKU KOGYO K.K.) 1 February 1984, * abstract *	1-9	

	-/-		
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	11 April 1995	Muellner, W	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	A : member of the same patent family, corresponding document		



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 93 20 1611

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.)
E	EP-A-0 446 961 (TAKEDA CHEMICAL INDUSTRIES LTD.) * page 2 - page 3, line 6 * * page 7, line 50 - page 8, line 11 * * page 8, line 25 - line 32; claims 12,17,20-27; examples 7,9 * ---	1-9	
E	EP-A-0 423 748 (TAKEDA CHEMICAL INDUSTRIES LTD.) * claims 11,16,19-31 * ---	1-9	
E	EP-A-0 237 200 (TAKEDA CHEMICAL INDUSTRIES LTD.) * claims 1,6,9,10 * -----	1-9	
			TECHNICAL FIELDS SEARCHED (Int.Cl.)
<p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	11 April 1995	Muellner, W	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 567 201 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
15.09.1999 Bulletin 1999/37

(51) Int. Cl.⁶: A61K 9/32, A61K 9/52,
A61K 9/54

(21) Application number: 93201611.6

(22) Date of filing: 16.04.1987

(54) Vehicles for oral administration of a specific pharmaceutically active acid labile substance

Vehikel für die orale Verabreichung säurelabiler Pharmaka

Véhicules pour l'administration orale de substances pharmaceutiques sensibles aux acides

(84) Designated Contracting States:
AT ES GR

• Morigaki, Satoshi
Taka-gun, Hyogo 677-01 (JP)
• Oda, Minoru
Nakatsu-shi, Ohita 871 (JP)
• Ohishi, Naohiro
Chikujo-gun, Fukuoka 871-09 (JP)

(30) Priority: 30.04.1986 GB 8610572

(74) Representative:
Linderoth, Margareta et al
Astra AB
Intellectual Property, Patents
151 85 Södertälje (SE)

(43) Date of publication of application:
27.10.1993 Bulletin 1993/43

(56) References cited:

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
92107179.1 / 0 496 437
87850127.9 / 0 247 983

EP-A- 0 080 602	EP-A- 0 124 495
EP-A- 0 173 664	EP-A- 0 237 200
EP-A- 0 423 748	EP-A- 0 446 961
DE-A- 3 233 764	GB-A- 760 403

• PATENT ABSTRACTS OF JAPAN vol. 8 no. 106
(C-223) [1543] ,18 May 1984 & JP-A-59 020219
(SHINETSU KAGAKU KOGYO K.K.) 1 February
1984,

(73) Proprietor: Astra Aktiebolag
151 85 Södertälje (SE)

(72) Inventors:

- Lövgren, Kurt
S-435 44 Mölnlycke (SE)
- Pilbrant, Ake
S-434 45 Kungsbacka (SE)
- Yasumura, Mitsuru
Nishinomiya, Hyogo 662 (JP)

EP 0 567 201 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The present invention is related to an improved administration vehicle for oral administration of omeprazole.

5 [0002] From e.g. EP-A1-0 005 129 omeprazole, 5-methoxy-2(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, a potent inhibitor of gastric acid secretion is known. Omeprazole shows a powerful inhibitory action against secretion of gastric juice (Lancet, Nov 27, 1982, p. 1223-1224) and can be used for the treatment of gastric and duodenal ulcers. Omeprazole is, however, susceptible to degradation/transformation in acid reacting and neutral media. The half-life of omeprazole in water solutions at pH-values less than four is shorter than ten minutes. Also at neutral pH-values the degradation reaction proceeds rapidly, e.g. at pH=7 the half-life of omeprazole is about 14 hours, while at higher pH-values the stability in solution is much better (Pilbrant and Cederberg, Scand. J. Gastroenterology 1985; 20 (suppl. 108) p. 113-120). The stability profile is similar in solid phase. The degradation of omeprazole is catalyzed by acidic reacting compounds and is stabilized in mixtures with alkaline reacting compounds. The stability of omeprazole is also affected by moisture and organic solvents.

10 [0003] From what is said about the stability properties of omeprazole, it is obvious that an oral dosage form of omeprazole must be protected from contact with the acid reacting gastric juice in order to reach the small intestine without degradation.

15 [0004] In human pharmacological studies it was found that the rate of release of omeprazole from a pharmaceutical dosage form can influence the total extent of absorption of omeprazole to the general circulation (Pilbrant and Cederberg, Scand. J. Gastroenterology 1985; 20 (suppl. 108) p. 113-120). A fully bioavailable dosage form of omeprazole must release the active drug rapidly in the proximal part of the gastrointestinal canal.

20 [0005] In order to obtain a pharmaceutical dosage form of omeprazole which prevents omeprazole from contact with acidic gastric juice, the cores must be enteric coated. Ordinary enteric coatings, however, are made of acidic compounds. If covered with such a conventional enteric coating, omeprazole rapidly decomposes by direct or indirect contact with it, with the result that the preparations become rapidly discolored and lose in omeprazole content with the

25 passage of time.

[0006] In order to enhance the storage stability the cores which contain omeprazole must also contain alkaline reacting constituents. When such an alkaline core is enteric coated with an amount of a conventional enteric coating polymer such as, for example, cellulose acetate phthalate, that permits the dissolution of the coating and the active drug contained in the cores in the proximal part of the small intestine, it also will allow some diffusion of water of gastric juice through the enteric coating into the cores, during the time the dosage form resides in the stomach before it is emptied into the small intestine. The diffused water of gastric juice will dissolve parts of the core in the close proximity of the enteric coating layer and there form an alkaline solution inside the coated dosage form. The alkaline solution will interfere with the enteric coating and eventually dissolve it.

30 [0007] An enteric coated dosage form of omeprazole was reported by Pilbrant and Cederberg, in the above cited Scand. J. Gastroenterology 1985; 20 (suppl. 108) p. 113-120. The publication describes a conventional enteric coated dosage form and states that it has an acceptable storage stability - for clinical studies. It was later found that the stability of this dosage form was insufficient during long-term storage required for a marketed pharmaceutical dosage form.

35 [0008] If a conventional formulation of omeprazole is made, the stability is not satisfactory, particularly in resistance to humidity, and special moisture-proof packing has been adopted to minimize the troubles. However, this provides no satisfactory solution to the problems in today's drug distribution system, and also leads to increased costs. Under the circumstances, there has been a demand for the development of new enteric preparations of omeprazole with better stability.

40 [0009] In DE-A1-3046 559 a way to coat a dosage form is described. First the dosage form is coated with a water insoluble layer containing microcrystalline cellulose and then with a second enteric coating with the aim to achieve a dosage form which releases the active drug in the colon. This method of preparation will not give the desired release of omeprazole in the small intestine.

45 [0010] US-A-2 540 979 describes an enteric coated oral dosage form, where the enteric coating is combined with a second and/or first coating of a water insoluble "wax" layer. This method of preparation is not applicable on cores containing omeprazole since direct contact between substances such as cellulose acetate phthalate (CAP) and omeprazole causes degradation and discolouration of omeprazole.

50 [0011] DE-B2-23 36 218 describes a method to produce a dialysis membrane consisting of a mixture of one or more conventional enteric coating polymers and one or more insoluble cellulose derivatives. Such a membrane will not give a proper protection of omeprazole in gastric juice.

55 [0012] DE-A1-1 204 363 describes a three-layer coating procedure. The first layer is soluble in gastric but is insoluble in intestinal juice. The second is water soluble regardless of pH and the third layer is an enteric coating. This preparation as well as the preparation described in DE-A1-1 617 615 result in a dosage form which is not dissolved in gastric juice and which only dissolves slowly in intestinal juice. Such preparations cannot be used for omeprazole, where a rapid release of the drug in the small intestine is needed.

[0013] DE-A1 12 04 363 describes coating with three layers to achieve release of a drug in the ileum, an aim which is outside the scope of the present invention.

[0014] GB-A-1 485 676 describes a way to obtain a preparation, which effervesces in the small intestine, by enteric coating a core containing the active drug and an effervescent system such as a combination of carbonate and/or bicarbonate salt and a pharmaceutically acceptable acid. The formulation cannot be adopted for a pharmaceutical dosage form containing omeprazole, as the presence of an acid in contact with omeprazole in the cores would give a result that omeprazole was degraded.

[0015] WO 85/03436 describes a pharmaceutical preparation, wherein cores containing active drugs mixed with for instance buffering components such as sodium dihydrogenphosphate with the aim of maintaining a constant pH and a constant rate of diffusion, are coated with a first coating which controls the diffusion. This formulation cannot be adopted for omeprazole where a rapid release in the small intestine is wanted. Direct application of an enteric coating onto the cores would also adversely influence the storage stability of such dosage forms containing omeprazole.

[0016] EP-A-124 495 describes enteric coated granules without subcoating or powder that are filled into hard gelatine capsules or a solution that is filled into soft capsules.

[0017] The object of the present invention is to provide an improved administration vehicle for oral administration of the pharmaceutically active acid labile substance omeprazole as claimed in claim 1. The administration vehicle makes the formulation stable to discolouration and resistant to dissolution in acid media. It dissolves rapidly in neutral to alkaline media and has a good stability during long-term storage. The formulation is characterized in the following way. Core material in the form of small beads or tablets containing omeprazole together with an alkaline reacting compound, or an alkaline salt of omeprazole optionally together with an alkaline reacting compound, and on said core material one or more inert reacting subcoating layers comprising tablet excipients which are soluble or rapidly disintegrating in water, or polymeric, water soluble, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the alkaline reacting core and an outer layer, which is an enteric coating. This/these inner layer/layers separates/separate the alkaline core material from the outer layer, which is an enteric coating. The final, enteric coated dosage form is treated in a suitable way to reduce the water content to a very low level in order to obtain a good stability of the dosage form during long-term storage.

Detailed description of the invention

30 Cores

[0018] Omeprazole is mixed with inert, preferably water soluble, conventional pharmaceutical constituents to obtain the preferred concentration of omeprazole in the final mixture and with an alkaline reacting, otherwise inert, pharmaceutically acceptable substance (or substances), which creates a "micro-pH" around each omeprazole particle of not less than pH=7, preferably not less than pH=8, when water is adsorbed to the particles of the mixture or when water is added in small amounts to the mixture. Such substances can be chosen among, but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as A₁O₃.6MgO.CO₂.12H₂O,(Mg₆A₁₂(OH)₁₆CO₃.4H₂O), MgO.A₁O₃.2SiO₂.nH₂O or similar compounds; organic pH-buffering substances such as trihydroxymethylaminomethane or other similar, pharmaceutically acceptable pH-buffering substances. The stabilizing, high pH-value in the powder mixture can also be achieved by using an alkaline reacting salt of omeprazole such as the sodium, potassium, magnesium, calcium etc. salts of omeprazole, which are described in e.g. EP-A2-124 495, either alone or in combination with a conventional buffering substance as previously described.

[0019] The powder mixture is then formulated into small beads i.e. pellets, or tablets, by conventional pharmaceutical procedures. The pellets or tablets are used as cores for further processing.

Separating layer

[0020] The omeprazole containing alkaline reacting cores must be separated from the enteric coating polymer(s) containing free carboxyl groups, which otherwise causes degradation/discolouration of omeprazole during the coating process or during storage. The subcoating layer, in the following defined as the separating layer, also serves as a pH-buffering zone in which hydrogen ions diffusing from the outside in towards the alkaline core can react with hydroxyl ions diffusing from the alkaline core towards the surface of the coated articles. The pH-buffering properties of the separating layer can be further strengthened by introducing in the layer substances chosen from a group of compounds usually used in antacid formulations such as, for instance, magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance A₁O₃6MgO.CO₂12H₂O, (Mg₆A₁₂(OH)₁₆CO₃.4H₂O), MgO.A₁O₃2SiO₂.nH₂O or similar compounds; or other phar-

aceutically acceptable pH-buffering compounds such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, citric or other suitable, weak, inorganic or organic acids.

[0021] The separating layer consists of one or more water soluble inert layer, optionally containing pH-buffering compounds.

- 5 [0022] The separating layer(s) can be applied to the cores - pellets or tablets - by conventional coating procedures in a suitable coating pan or in a fluidized bed apparatus using water and/or conventional organic solvents for the coating solution. The material for the separating layer is chosen among the pharmaceutically acceptable, water soluble, inert compounds or polymers used for film-coating applications such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, methycellulose, hydroxymethyl cellulose,
- 10 hydroxypropyl methylcellulose or polyvinyl acetal diethylaminoacetate. The thickness of the separating layer is not less than 2 µm, for small spherical pellets preferably not less than 4 µm, for tablets preferably not less than 10 µm.
- [0023] In the case of tablets another method to apply the coating can be performed by the drycoating technique. First a tablet containing omeprazole is compressed as described above. Around this tablet a layer is compressed using a suitable tableting machine. The outer, separating layer, consists of pharmaceutically acceptable, in water soluble or in
- 15 water rapidly disintegrating tablet excipients. The separating layer has a thickness of not less than 1 mm. Ordinary plasticizers colorants, pigments, titanium dioxide, talc and other additives may also be included into the separating layer.

Enteric coating layer

- 20 [0024] The enteric layer coating layer is applied on to the subcoated cores by conventional coating techniques such as, for instance, pan coating or fluidized bed coating using solutions or polymers in water and/or suitable organic solvents or by using latex suspensions on said polymers. As enteric coating polymers can be used, for example, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters such as, for instance, compounds known under the trade name Eudragit® L 12,5 or Eudragit® L 100 (Röhm Pharma), or similar compounds used to obtain enteric coatings. The enteric coating can also be applied using water-based polymer dispersions, e.g. Aquateric® (FMC Corporation), Eudragit® L100-55 (Röhm Pharma), Coating CE 5142 (BASF). The enteric coating layer can optionally contain a pharmaceutically acceptable plasticizer such as, for instance, cetanol, triacetin, citric acid esters such as, for instance, those known under the trade name Citroflex® (Pfizer), phthalic acid esters, dibutyl succinate or similar plasticizers. The amount of plasticizer is usually optimized for each enteric coating polymer(s) and is usually in the range of 1-20 % of the enteric coating polymer(s). Dispersants such as talc, colorants and pigments may also be included into the enteric coating layer.
- [0025] Thus, the special preparation according to the invention consists of cores containing omeprazole mixed with an alkaline reacting compound or cores containing an alkaline salt of omeprazole optionally mixed with an alkaline reacting compound. The alkaline reacting core material and/or alkaline salt of the active ingredient, omeprazole, enhance the stability of omeprazole. The cores suspended in water forms a solution or a suspension which has a pH, which is higher than that of a solution in which the polymer used for enteric coating is just soluble. The cores are coated with an inert reacting water soluble or in water rapidly disintegrating coating, optionally containing a pH-buffering substance, which separates the alkaline cores from the enteric coating. Without this separating layer the resistance towards gastric juice would be too short and/or the storage stability of the dosage form would be unacceptably short. The sub-coated dosage form is finally coated with an enteric coating rendering the dosage form insoluble in acid media, but rapidly disintegrating/dissolving in neutral to alkaline media such as, for instance the liquids present in the proximal part of the small intestine, the site where dissolution is wanted.

Final dosage form

- [0026] The final dosage form is either an enteric coated tablet or capsule or in the case of enteric coated pellets, pellets dispensed in hard gelatin capsules or sachets or pellets formulated into tablets. It is essential for the long term stability during storage that the water content of the final dosage form containing omeprazole (enteric coated tablets, capsules or pellets) is kept low, preferably not more than 1.5 % by weight. As a consequence the final package containing hard gelatin capsules filled with enteric coated pellets preferably also contain a desiccant, which reduces the water content of the gelatin shell to a level where the water content of the enteric coated pellets filled in the capsules does not exceed 1.5 % by weight.

Process

[0027] A process for the manufacture of the oral dosage form represents a further aspect of the invention. After the forming of the cores the cores are first coated with the separating layer and then with the enteric coating layer. The coat-

ing is carried out as described above.

[0028] The preparation according to the invention is especially advantageous in reducing gastric acid secretion and/or providing a gastrointestinal cytoprotective effect. It is administered one to several times a day. The typical daily dose of the active substance varies and will depend on various factors such as the individual requirements of the patients, the mode of administration and disease. In general the daily dose will be in the range of 1-400 mg of omeprazole.

[0029] The invention is described in detail in the following examples:

EXAMPLES

10 Example 1

[0030] The effect of different magnesium compounds was evaluated in the form of enteric coated tablets. Tablet cores were first made by known techniques according to the formulations listed in Table 1, followed by application of separating layers and enteric coating layers shown in Table 2.

15

Table 1

Formulations No.	1	2	3	4	5	6	7
Omeprazol	15.0	15.0	15.0	15.0	15.0	15.0	15.0
Lactose	134.0	119.0	119.0	119.0	118.8	118.5	119.0
Hydroxypropyl cellulose (low substitution)	5.0	5.0	5.0	5.0	5.0	5.0	5.0
Hydroxypropyl cellulose	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Talc	5.0	5.0	5.0	5.0	5.0	5.0	5.0
Na ₂ HPO ₄	-	15.0	-	-	0.2	-	-
Na lauryl sulfate	-	-	-	-	-	0.5	-
MgO	-	-	15.0	-	-	-	-
Mg(OH) ₂	-	-	-	15.0	15.0	15.0	-
Synthetic hydrotalcite [Al ₂ O ₃ .6MgO.CO ₂ .12H ₂ O]	-	-	-	-	-	-	15.0
Total	160.0	160.0	16.0	160.0	160.0	160.0	160.0

40

Table 2

Formulation No.	I	II	III	IV
Separating layer (inner):				
Hydroxypropyl cellulose	-	2.0	2.0	2.0
Magnesium hydroxide	-	-	0.3	-
Synthetic hydrotalcite	-	-	-	0.3
Separating layer (outer):				
Hydroxypropyl cellulose	-	2.0	2.0	2.0
Enteric coating layer:				
Hydroxypropyl methylcellulose phthalate	7.0	7.0	7.0	7.0
Cetyl alcohol	0.5	0.5	0.5	0.5

[0031] The tablets thus obtained were stored in open form under so called accelerated conditions, that is 40°C, and 75% relative humidity, and the changes in appearance with the passage of time were observed. Storage for six months under these conditions corresponds to storage at normal temperature for three years. This means that high stability sufficient for practical use may be assured if a drug remains intact for about one week under the mentioned conditions. The result is summarized in Table 3. As may be seen from the table, a remarkable stabilizing effect is achieved when a magnesium compound is contained in the inner layer.

Table 3

		Stabilizing Effect (Appearance of Preparations)						
		Coating Layer		Core material				
		1	2	3	4	5	6	7
I	At the start	C	A	A	A	A	A	A
	60°C; after 7 days	E	D	C	C	C	C	D
	40°C; 75% RH; after 7 days	F	E	B	B	B	B	E
II	At the start	A	A	A	A	A	A	A
	60°C; after 7 days	E	B	A	A	A	A	C
	40°C; 75% RH; after 7 days	E	D	A	A	A	A	D
III	At the start	A	A	A	A	A	A	A
	60°C; after 15 days	B	A	A	A	A	A	A
	40°C; after 30 days	A	A	A	A	A	A	A
IV	At the start	A	A	A	A	A	A	A
	60°C; after 15 days	B	A	A	A	A	A	A
	40°C; 75% RH; after 15 days	B	A	A	A	A	A	A

A: white, B: brownish white, C: faint brown, D: light brown, E: brown, F: deep brown.

[0032] All the samples evaluated as A (white) in the above table showed no discoloration even on split surfaces. The samples evaluated as B (brownish white) showed little change in appearance, but some discoloration was observed on split surfaces.

[0033] Table 4 shows the result of a stability test on the omeprazole preparation according to Example 1 (Formulation No 4-IV). The formulation was stored in a closed glass bottle at room temperature for the indicated period of time. This clearly demonstrates that preparations with unusually high stability were obtained.

Table 4

Stability of enteric coated omeprazole preparations (Tablets of Formulation No.4-IV)		
Storage Period	Appearance	Omeprazole Content(%)
At the start of test	White	100.0
1 year at room temp.	White	99.9
2 years at room temp.	White	100.0

Example 2

[0034]

5

10

15

20

25

Uncoated pellets		
	I	
10	Mannitol powder	16 150 g
	Lactose anhydrous	800 g
	Hydroxypropyl cellulose	600 g
	Microcrystalline cellulose	400 g
15	Omeprazole	2 000 g
	Sodium lauryl sulphate	50 g
	Disodium hydrogen phosphate	80 g
	Distilled water	4 400 g

30

[0035] The dry ingredients (I) were premixed in a mixer. Addition of a granulation liquid (II) containing suspended omeprazole was made and the mass was wet-mixed to a proper consistency. The wet mass was pressed through an extruder and spheronized to pellets. The pellets were dried and classified into suitable particle size ranges.

Subcoated pellets		
	III	
30	Uncoated omeprazole pellets	6 000 g
	Hydroxypropyl methylcellulose	240 g
	Distilled water	4 800 g

35 [0036] The polymer solution (III) was sprayed on the uncoated pellets in a fluidized bed apparatus. The spray guns were placed above the fluidized bed.

40

45

Enteric-coated pellets		
	IV	
40	Subcoated pellets	500 g
	Hydroxypropyl methylcellulose phthalate	57 g
	Cetyl alcohol	3 g
	Acetone	540 g
	Ethanol	231 g

50 [0037] The polymer solution (IV) was sprayed on the subcoated pellets in a fluidized bed apparatus with spray guns placed above the bed. After drying to a water content of 0.5 % the enteric coated pellets were classified and filled into hard gelatin capsules in an amount of 225 mg, corresponding to 20 mg of omeprazole. 30 capsules were packed in tight containers together with a desiccant.

55 Example 3

[0038] This example illustrates that a variety of polymers can be used for subcoating, e.g. hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohols.

Uncoated pellets		
	I	
10	Mannitol powder	1 620 g
	Lactose anhydrous	80 g
	Hydroxypropyl cellulose	60 g
	Microcrystalline cellulose	40 g
	Omeprazole	200 g
	Sodium lauryl sulphate	1.0 g
15	Disodium hydrogen phosphate	9.3 g
	Distilled water	515 g

[0039] The uncoated pellets were prepared as described in Example 2.

Subcoated pellets		
	III	
25	Uncoated omeprazole pellets	500 g
	Polyvinylpyrrolidone	20 g
	Ethanol	400 g

[0040] The subcoated pellets were prepared as described in Example 2.

Enteric-coated pellets		
	IV	
35	Subcoated pellets	500 g
	Hydroxypropyl methylcellulose phthalate	45 g
	Cetyl alcohol	5 g
	Acetone	219 g
	Ethanol	680 g

[0041] The enteric-coated pellets were prepared as described in Example 2.

45 Example 4

[0042]

Uncoated pellets		
	I	
55	Mannitol powder	1 610 g
	Lactose anhydrous	80 g
	Hydroxypropyl cellulose	60 g
	Microcrystalline cellulose	40 g

(continued)

Uncoated pellets			
	II	Omeprazole Pluronic® F68 Disodium hydrogen phosphate Distilled water	200 g 10 g 24 g 450 g
5			

10 [0043] The uncoated pellets were prepared as described in Example 2.

Subcoated pellets			
	III	Uncoated pellets Polyvinylpyrrolidone Ethanol	500 g 30 g 400 g
15			
20			

[0044] The subcoated pellets were prepared as described in Example 2.

Enteric coated pellets			
	IV	Subcoated pellets Hydroxypropyl methylcellulose phthalate Cetyl alcohol Methylene chloride Ethanol	500 g 45 g 5 g 371 g 680 g
25			
30			
35			

[0045] The enteric coated pellets were prepared as described in Example 2.

Example 5

40 [0046] This example illustrates that a variety of polymers can be used as enteric coating material e.g. cellulose acetate phthalate, poly-(vinyl acetate/vinyl alcohol phthalate), hydroxypropyl methyl cellulose phthalate, poly-(methacrylic acid/methacrylic acid methyl esters), poly-(acrylic acid/methacrylic acid methyl esters). The polymers can be applied with/without plasticizer, e.g. polyethylene glycols, triacetin, dimethyl polysiloxan, Citroflex®, cetyl alcohol, stearyl alcohol, diethyl phthalate.

45 [0047] Enteric-coated pellets can also be manufactured from water-based polymer dispersions, e.g. Aquateric®(FMC Corporation), Eudragit®L 100-55, Coating CE 5142 (BASF).

Uncoated pellets			
	I	Lactose powder Lactose anhydrous Hydroxypropyl cellulose Colloidal silica	277 g 118 g 25 g 25 g
50			
55			

(continued)

Uncoated pellets			
II	Omeprazole Sodium lauryl sulphate Disodium hydrogen phosphate Sodium dihydrogen phosphate Distilled water	50 g 5 g 2 g 0.1 g 170 g	

[0048] The uncoated pellets were prepared as described above.

Subcoated pellets

[0049] The uncoated pellets were subcoated as described in Example 2.

Enteric coated pellets			
III	Subcoated pellets Eudragit® L 500 Stearyl alcohol Ethanol	500 g 45 g 4.5 g 1 320 g	

[0050] The enteric coated pellets were prepared as described above.

Example 6

Formulations with the sodium salt of omeprazole.

[0051]

Uncoated pellets			
I	Omeprazole sodium salt Mannitol powder Lactose anhydrous Hydroxypropyl cellulose Microcrystalline cellulose II	339 g 2 422 g 120 g 90 g 60 g Sodium lauryl sulphate Distilled water	7 g 650 g

[0052] The preparation was made as described in Example 2 with the exception that the omeprazole sodium salt was added together with the other ingredients in mixture I.

55

Subcoated pellets			
	III	Uncoated pellets	500 g
5		Hydroxypropyl methylcellulose	20 g
		Aluminium hydroxide/magnesium carbonate	4 g
10	IV	Distilled water	400 g
		Pellets subcoated with III	500 g
		Hydroxypropyl methylcellulose	20 g
15		Distilled water	400 g

[0053] The two subcoat layers, III and IV, were applied to the uncoated pellets in a fluidized bed apparatus in consecutive order as previously described.

20

Enteric coated pellets			
	V	Subcoated pellets	500 g
25		Hydroxypropyl methylcellulose phthalate	57 g
		Cetyl alcohol	3 g
		Acetone	540 g
30		Ethanol	231 g

[0054] The preparation of enteric coated pellets was performed as described in Example 2.

Examples 7 and 8

35

[0055] Formulations with the magnesium salt of omeprazole.

40

		Uncoated pellets		Example No	
				7	8
45	I	Omeprazole magnesium salt	222 g	222 g	
		Mannitol powder	1 673 g	1 473 g	
		Microcrystalline cellulose	100 g	100 g	
		Magnesium hydroxide	-	200 g	
50	II	Sodium lauryl sulphate	5 g	5 g	
		Distilled water	500 g	375 g	

[0056] The preparation was made as described in Example 2 with the exception that the omeprazole salt was added together with the other ingredients in mixture I.

55

5

Subcoated pellets		Examples 7 and 8
III	Uncoated pellets Hydroxypropyl methylcellulose Distilled water	500 g 20 g 400 g

10

[0057] The pellets were prepared as described in Example 2.

15

Enteric coated pellets		Examples 7 and 8
IV	Subcoated pellets Hydroxypropyl methylcellulose phthalate Cetyl alcohol Acetone Ethanol	500 g 57 g 3 g 540 g 231 g

20

25 Examples 9 and 10

25

[0058] Manufacture of tablets.

30

Tablet cores		Examples No	
		9	10
I	Omeprazole Omeprazole sodium salt, corresponding to omeprazole 400 g Lactose, anhydrous Polyvinylpyrrolidone, crosslinked Sodium carbonate, anhydrous Methyl cellulose Distilled water Magnesium stearate	400 g - 1 420 g 100 g 15 g 12 g 200 g 30 g	- 426 g 1 406 g 100 g - 12 g 200 g 30 g

35

40

45

[0059] The powder mixture I was carefully homogenized and granulated by the solution II. The wet mass was dried in a fluidized bed dryer using an inlet air temperature of +50°C for 30 minutes. The dried mixture was then forced through a sieve with an aperture of 0.5 mm. After mixing with magnesium stearate the granulate was tabletted on a tabletting machine using 6 mm punches. The tablet weight was 100 mg.

Subcoating

[0060] The tablets containing omeprazole were subcoated with approximately 10 % by weight of hydroxypropyl methylcellulose from a water solution using a perforated coating pan apparatus.

[0061] The tablets containing omeprazole sodium salt were subcoated using the dry coating technique. A tablet granulate containing

5	Lactose anhydrous	4 000 g
	Polyvinylpyrrolidone, (PVP)	180 g
	Ethanol 95 %	420 g
	Magnesium stearate	42 g

10 was prepared in the following way. The lactose was granulated with a solution of PVP in ethanol and dried. After drying magnesium stearate was admixed.

[0062] The granulate mass was dry coated around the tablet cores of Example 9 using a Manesty Dry Cota® tabletting machine. The tablet weight of the dry coated tablets was 475 mg. Each tablet contained 20 mg of omeprazole.

15 Enteric coating

[0063] The subcoated tablets obtained above were enteric coated using the same coating solution:

20

25	Hydroxypropyl methylcellulose phthalate	1 500 g
	Cetyl alcohol	105 g
	Methylene chloride	15 000 g
	Isopropanol	15 000 g
	Distilled water	3 150 g

30

[0064] The coating was applied in a perforated coating pan apparatus. An approximate amount of one kg of coating solution was applied for each kg of tablets.

COMPARATIVE EXAMPLES

35

Examples I, II and III

[0065] These examples illustrate that the buffer salt used effects the enteric-coated omeprazole pellets properties when the sub-coating layer is absent. A high amount of buffer salt is needed in order to obtain a long shelf life for the product. At the same time this type of pellets shows inferior acid resistance properties. C.f. also the Example 4 above.

45

	Uncoated pellets		Examples No		
			I	II	III
50	I	Mannitol powder	1 610 g	1 610 g	1 610 g
		Lactose anhydrous	80 g	80 g	80 g
		Hydroxypropyl cellulose	60 g	60 g	60 g
		Microcrystalline cellulose	40 g	40 g	40 g
	II	Omeprazole	200 g	200 g	200 g
		Pluronic®F68	10 g	10 g	10 g
		Disodium hydrogen phosphate	2 g	8 g	24 g
		Distilled water	450 g	450 g	450 g

[0066] The uncoated pellets were prepared as described in Example 2 above.

Enteric coated pellets			
	III	Uncoated pellets	500 g
5		Hydroxypropyl methylcellulose phthalate	45 g
10		Cetyl alcohol	5 g
		Methylene chloride	371 g
		Ethanol	680 g

15 [0067] The coated pellets were prepared as describee in Example 2 above.

Example IV

[0068] This formulation is the same as in Example 6 above, but no subcoating layer was used.

20

Uncoated pellets			
	I	Omeprazole sodium salt	339 g
25		Mannitol powder	2 422 g
		Lactose anhydrous	120 g
30		Hydroxypropyl cellulose	90 g
		Microcrystalline cellulose	60 g
	II	Sodium lauryl sulphate	7 g
		Distilled water	650 g

35

[0069] The preparation was made as described in Example 6.

40

Enteric-coated pellets			
	III	Uncoated pellets	500 g
45		Hydroxypropyl methylcellulose phthalate	57 g
		Cetyl alcohol	3 g
		Acetone	540 g
55		Ethanol	231 g

50 [0070] The enteric coated pellets were prepared as described in Example 2.

Example V

[0071] This formulation is the same as in Example 8 above, but no subcoating layer was used.

55

5

10

15

20

25

30

35

Acid resistance

[0075] The following resistance of the formulations was studied in the following way: The formulations were added to gastric fluid USP (without enzyme), 37°C (paddle) 100 r/min. After 2 hours the actual amount of omeprazole remaining intact in the formulations was determined.

Rate of dissolution in buffer solution

[0076] In order to establish the rate of dissolution in the small intestine the formulations were added to a buffer solution. Buffer solution 37°C, USP dissolution apparatus No 2 (paddle), 100 r/min. After 10 or 30 minutes the amount of omeprazole dissolved was determined. The results are presented in the following Table 5.

50

55

Uncoated pellets		
I	Omeprazole magnesium salt	222 g
	Mannitol powder	1 473 g
	Microcrystalline cellulose	100 g
	Magnesium hydroxide	200 g
	Sodium lauryl sulphate	5 g
	Distilled water	375 g

Enteric coated pellets		
III	Uncoated pellets	500 g
	Hydroxypropyl methylcellulose phthalate	57 g
	Cetyl alcohol	3 g
	Acetone	540 g
	Ethanol	231 g

[0073] The pellets were prepared as described in Example 2 above.

Properties of the enteric coated pellets

[0074] For the preparations according to Examples 2-8 and comparative Examples I-V above one or both of the following studies have been performed.

Acid resistance

[0075] The following resistance of the formulations was studied in the following way: The formulations were added to gastric fluid USP (without enzyme), 37°C (paddle) 100 r/min. After 2 hours the actual amount of omeprazole remaining intact in the formulations was determined.

Rate of dissolution in buffer solution

[0076] In order to establish the rate of dissolution in the small intestine the formulations were added to a buffer solution. Buffer solution 37°C, USP dissolution apparatus No 2 (paddle), 100 r/min. After 10 or 30 minutes the amount of omeprazole dissolved was determined. The results are presented in the following Table 5.

Table 5

Example No	Omeprazole content mg/g	Acid resistance amount intact omeprazole (%) after 2 hours	% dissolved at different after 10 or		omeprazole pH:s and 30 min
			%	pH	
2	89.2	96	100	6.8	10
3	90	96	91	6.0	10
4	88	89	*)		
5	82	93	70	7.5	30
6	81.3	87	93	6.8	10
7	91	95	**)		
8	89	98	**)		
I	93	97	*)		
II	92	94	*)		
III	94	58	*)		
IV	86.5	4			
V	91	93	**)		

*) The stability of the formulation was studied during storage in glass bottles also containing a desiccant device. After one month storage at +50°C the formulation according to Example 4 was virtually intact with no change in appearance or physicochemical characteristics. Pellets according to Example I and II turned brown due to degradation, while the pellets according to Example III retained to original white colour.

**) The formulations according to Examples 7 and 8 were white and not affected by the coating process. The enteric coated pellets according to Example V, where the enteric coating was applied directly on the cores according to Example 8, was discoloured already during the enteric coating process.

Further comparative test

[0077] This example demonstrates the effect of the moisture content of the preparations according to the invention on storage stability.

[0078] The stability of omeprazole pellets according to the invention was compared with that of omeprazole pellets with higher water content. Omeprazole pellets were prepared according to the invention with a water content of 1 %. Two other portions of the same formulation were conditioned to a water content of 2 % and 5 % respectively. The three formulations, packed in tight containers not containing a desiccant, were stored for one month at + 50°C. After this time the packages were opened and the pellets were assayed for the amount of omeprazole by HPLC. The formulation according to the invention had an omeprazole content of 98.5 % of the initial value. The other two formulations with a water content of 2 and 5 % respectively were totally degraded and had only trace amounts of intact omeprazole.

DISCUSSION

[0079] From the results given in Table 5 it can be seen that formulations containing omeprazole with acceptable acid resistance can be prepared by using a conventional enteric coating technique (see for instance Examples I, II and V). However, it is also obvious that the storage stability of the formulations according to Examples I, II and V is not acceptable, since a discolouration, showing a degradation of omeprazole, occurs during short storage at an elevated storage temperature (Examples I and II) or already during the enteric coating process (Example V).

[0080] If the amount of alkaline substances in the cores is increased to a level where omeprazole has an acceptable storage stability (Example III) or if an alkaline reacting salt of omeprazole is used in the preparation of the cores (Example IV), then, without the separating layer of the invention, the resistance to dissolution in acid media becomes unacceptably low and much or all of the active substance will degrade already in the stomach and thus, it has no effect on

the gastric acid secretion.

[0081] When the preparation is carried out to the invention as for instance in Example 4, a good resistance towards gastric juice as well as a good stability during long-term storage is obtained. This is in contrast with the formulations in Examples I, II and III where either an acceptable acid resistance or an acceptable storage stability can be achieved - but not both. The same comparison can be made between the formulations according to Examples 7 and 8 according to the invention and the formulation according to Example V, where the separating layer was omitted. Examples 7 and 8 differ in that a buffering substance, magnesium hydroxide, has been included in the cores of Example 8. This further improves the acid resistance as well as the storage stability of Example 8 in comparison with Example 7.

[0082] The further comparative test shows the great importance of a low water content in the preparations.

[0083] Thus, in order to prepare pharmaceutical formulations of omeprazole for oral use, which exert good stability during long-term storage as well as good stability during the residence in the stomach after administration, the preparation is made in the following way:

a) Omeprazole together with an alkaline reacting compound or compounds or an alkaline reacting salt of omeprazole optionally mixed with alkaline reacting compound are included in the core material.

b) The core material is subcoated with one or more inert, in water soluble or in water rapidly disintegrating layers, which separate the alkaline reacting core from the enteric coating. The subcoating layer may optionally contain pH-buffering compounds.

c) The subcoated cores are coated with an acid insoluble enteric coating, optionally containing plasticizers.

Biopharmaceutical studies

[0084] The hard gelatin capsules according to Example 2 were administered to 12 healthy, young male volunteers in the following way:

[0085] The volunteers came to the laboratory in the morning after having abstained from food since 10 p.m. the night preceding the experimental day. A zero time blood sample was taken. One omeprazole capsule according to Example 2 was administered together with 150 ml of tap water. Further blood samples were taken during the day.

[0086] In another experiment the same volunteers were administered 20 mg of omeprazole in the form of a suspension of micronized omeprazole in a sodium bicarbonate water solution. In order to reduce the degradation of omeprazole in the stomach to a minimum, solid bicarbonade solution was given to the subjects just before the administration of the omeprazole suspension and at further four times with a 10-minutes interval after the drug intake. The concentration of omeprazole in blood plasma was assayed by high pressure liquid chromatography (Persson, Lagerström and Grundevik. Scand J Gastroenterol 1985, 20, (suppl 108), 71-77. The mean plasma concentrations are given in Table 6.

Table 6

The plasma concentrations ($\mu\text{mol/l}$) after 20 mg single oral doses of omeprazole given as hard gelatin capsules according to Example 2 and as a suspension of micronized omeprazole in sodium bicarbonate solution.			
	Time (min)	Capsules	Suspension
	10		0.84
	20		0.90
	30	0.03	0.84
	45		0.64
	60	0.22	0.44
	90	0.36	0.24
	120	0.39	0.13
	150	0.29	
	180	0.20	0.04
	210	0.10	

Table 6 (continued)

The plasma concentrations ($\mu\text{mol/l}$) after 20 mg single oral doses of omeprazole given as hard gelatin capsules according to Example 2 and as a suspension of micronized omeprazole in sodium bicarbonate solution.		
Time (min)	Capsules	Suspension
240	0.05	0.01
300	0.02	0
360	0.01	
420	0	

[0087] Although the plasma concentration peak at different times, the two formulations are bioequivalent. The mean relative bioavailability of the capsules in comparison with the suspension was 85 % +23 % (S.D.). The comparison was based on the total area under individual plasma concentration versus times curves.

[0088] Thus, by preparing capsules according to the invention it is possible to obtain a preparation with the same bioavailability as a suspension containing the same amount to micronized active compound. It is, however, to be noticed that when the suspension is administered, the patients must also be given sodium bicarbonate solution frequently in order to minimize pre-absorption degradation of omeprazole in the stomach.

Claims

1. Improved administration vehicle for oral administration of pharmaceutically active acid labile substances prone to discolouration, comprising:
 - i) a core containing the pharmaceutically active acid labile substance,
 - ii) a subcoating applied on said core and
 - iii) an enteric coating applied on said subcoating,
 characterized in that:
 - iv) the subcoating part of the vehicle is made out of one or more inert reacting layers, comprising tablet excipients,
 - v) the excipients are soluble or rapidly disintegrating in water, or polymeric, water soluble, filmforming compounds, optionally containing pH-buffering alkaline compounds,
 - vi) the core part of the vehicle contains omeprazole, as the pharmaceutically active acid labile substance to be administered together with an alkaline substance
 - vii) the alkaline substance in vi) is an alkaline reacting compound or an alkaline salt of omeprazole optionally mixed with an alkaline compound, and
 - viii) the vehicle adopts the form of a number of small beads optionally forming a tablet or a tablet as such.
2. Improved administration vehicle according to claim 1, wherein the subcoating of the core containing omeprazole comprises hydroxypropyl methycellulose, hydroxypropyl cellulose or polyvinyl-pyrrolidone.
3. Improved administration vehicle according to claim 1 wherein the applied subcoating comprises two or more sub-layers and where the inner sub-layer contains one or more of magnesium oxide, magnesium hydroxide or composite substance $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$ or $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$, wherein n not is an integer and less than two.
4. Improved administration vehicle according to claim 1 wherein the omeprazole containing core comprises omeprazole mixed with a pH-buffering alkaline compound rendering to the microenvironment of the omeprazole a pH of 7-12.
5. Improved administration vehicle according to claim 4 wherein the alkaline compound which the omeprazole is mixed with comprises one or more of magnesium oxide, hydroxide or carbonate, aluminium, calcium, sodium or potassium carbonate, phosphate or citrate, the composite aluminium/magnesium compounds $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$ or $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$, wherein n not is an integer and less than two.
6. Improved administration vehicle according to claim 4 wherein the alkaline core comprises an alkaline salt of omeprazole such as the sodium, potassium, magnesium, calcium or ammonium salt.

7. Improved administration vehicle according to claim 4 wherein the alkaline core comprises an alkaline salt of omeprazole mixed with an otherwise alkaline compound.
- 5 8. Improved administration vehicle according to claim 1 wherein the enteric outer coating comprises hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, co-polymerized methacrylic acid/methacrylic acid methyl ester or polyvinyl acetate phthalate, optionally containing a plasticizer.
9. Improved administration vehicle according to claim 1 which has a water content which does not exceed 1,5% by weight.

10

Patentansprüche

1. Verbessertes Verabreichungsvehikel zur oralen Verabreichung von säurelabilen pharmazeutischen Wirkstoffen, die sich leicht verfärben, enthaltend:
 - 15 i) einen Kern, der den säurelabilen pharmazeutischen Wirkstoff enthält,
 - ii) eine untere Beschichtung, die auf den Kern aufgetragen ist, und
 - iii) einen enterischen Bezug, der auf die untere Beschichtung aufgetragen ist, dadurch gekennzeichnet, daß
 - iv) die untere Beschichtung des Vehikels aus einer oder mehreren inerten reagierenden Schichten besteht, die Tablettenträgerstoffe enthalten,
 - v) die Trägerstoffe wasserlöslich sind bzw. schnell in Wasser zerfallen, oder polymere wasserlösliche filmbildende Verbindungen sind, die gegebenenfalls pH-puffernde alkalische Verbindungen enthalten,
 - vi) der Kern des Vehikels Omeprazol als säurelabilen pharmazeutischen Wirkstoff enthält, der zusammen mit der alkalischen Substanz verabreicht werden soll,
 - 20 vii) die alkalische Substanz in vi) eine alkalische reagierende Verbindung oder ein alkalisches Omeprazolsalz ist, die oder das gegebenenfalls mit einer alkalischen Verbindung gemischt vorliegt, und
 - viii) das Vehikel die Form einer Anzahl kleiner Perlen, die gegebenenfalls eine Tablette bilden, oder einer Tablette als solcher hat.
2. Verbessertes Verabreichungsvehikel gemäß Anspruch 1, dadurch gekennzeichnet, daß die untere Beschichtung des Omeprazol enthaltenden Kerns aus Hydroxypropylmethylcellulose, Hydroxypropylcellulose oder Polyvinylpyrrolidon besteht.
3. Verbessertes Verabreichungsvehikel gemäß Anspruch 1, dadurch gekennzeichnet, daß die aufgetragene untere Beschichtung aus zwei oder mehr Unterschichten besteht, wobei die innere Unterschicht eine oder mehrere der folgenden Verbindungen enthält: Magnesiumoxid, Magnesiumhydroxid oder den Verbundstoff Al₂O₃.6MgO.CO₂.12H₂O oder MgO.Al₂O₃.2SiO₂.nH₂O, wobei n keine ganze Zahl und kleiner als zwei ist.
4. Verbessertes Verabreichungsvehikel gemäß Anspruch 1, dadurch gekennzeichnet, daß der Omeprazol enthaltende Kern eine Mischung von Omeprazol mit einer pH-puffernden alkalischen Verbindung enthält, die der Mikroumgebung des Omeprazol einen pH von 7-12 verleiht.
5. Verbessertes Verabreichungsvehikel gemäß Anspruch 4, dadurch gekennzeichnet, daß die alkalische Verbindung, mit der Omeprazol gemischt ist, eine oder mehrere der folgenden Verbindungen enthält: Magnesiumoxid, -hydroxid oder -carbonat, Aluminium-, Calcium-, Natrium- oder Kaliumcarbonat, -phosphat oder -citrat, die Aluminium/Magnesium-Verbundstoffe Al₂O₃.6MgO.CO₂.12H₂O oder MgO.Al₂O₃.2SiO₂.nH₂O, wobei n keine ganze Zahl und kleiner als zwei ist.
6. Verbessertes Verabreichungsvehikel gemäß Anspruch 4, dadurch gekennzeichnet, daß der alkalische Kern ein alkalisches Omeprazolsalz wie z. B. das Natrium-, Kalium-, Magnesium-, Calcium- oder Ammoniumsalz, enthält.
7. Verbessertes Verabreichungsvehikel gemäß Anspruch 4, dadurch gekennzeichnet, daß der alkalische Kern ein alkalisches Omeprazolsalz in einer Mischung mit einer ansonsten alkalischen Verbindung enthält.
- 55 8. Verbessertes Verabreichungsvehikel gemäß Anspruch 1, dadurch gekennzeichnet, daß der enterische äußere Bezug Hydroxypropylmethylcellulosephthalat, Celluloseacetatphthalat, ein Methacrylsäure-Methacrylsäuremethylester-Copolymerisat oder Polyvinylacetatphthalat und gegebenenfalls einen Weichmacher enthält.

9. Verbessertes Verabreichungsvehikel gemäß Anspruch 1, dadurch gekennzeichnet, daß sein Wassergehalt 1,5 Gewichtsprozente nicht überschreitet.

Revendications

5 1. Véhicule d'administration amélioré pour l'administration orale de substances pharmaceutiquement actives, sensibles aux acides et dont la couleur est susceptible d'être altérée, comprenant :

10 i) un cœur contenant la substance pharmaceutiquement active, sensible aux acides,
 ii) un sous-enrobage appliqué sur ledit cœur, et
 iii) un enrobage entérique appliqué sur ledit sous-enrobage, caractérisé en ce que :
 iv) la partie sous-enrobage du véhicule est constituée d'une ou de plusieurs couches réagissant de manière inerte, comprenant des excipients de comprimé,
 v) les excipients sont solubles ou se désagrègent rapidement dans l'eau, ou des composés polymères hydro-solubles filmogènes, contenant éventuellement des composés alcalins tampons,
 vi) la partie cœur du véhicule contient de l'omeprazole, en tant que substance pharmaceutiquement active, sensible aux acides, destinée à être administrée conjointement avec une substance alcaline,
 vii) la substance alcaline dans vi) est un composé réagissant de manière alcaline ou un sel alcalin de l'omeprazole, éventuellement mélangé avec un composé alcalin, et
 20 viii) le véhicule adopte la forme d'un certain nombre de petites billes formant éventuellement un comprimé, ou d'un comprimé en tant que tel.

25 2. Véhicule d'administration amélioré selon la revendication 1, dans lequel le sous-enrobage du cœur contenant de l'omeprazole comprend de l'hydroxypropylméthylcellulose, de l'hydroxypropylcellulose ou de la polyvinylpyrrolidone.

30 3. Véhicule d'administration amélioré selon la revendication 1, dans lequel le sous-enrobage appliqué comprend deux sous-couches ou plus et où la sous-couche interne contient l'un ou plusieurs parmi l'oxyde de magnésium, l'hydroxyde de magnésium ou la substance composite $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$ ou $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$, où n n'est pas un entier et est inférieur à deux.

35 4. Véhicule d'administration amélioré selon la revendication 1, dans lequel le cœur contenant de l'omeprazole comprend de l'omeprazole mélangé avec un composé alcalin tampon conférant un pH de 7-12 au micro-environnement de l'omeprazole.

40 5. Véhicule d'administration amélioré selon la revendication 4, dans lequel le composé alcalin avec lequel est mélangé l'omeprazole, comprend l'un ou plusieurs parmi l'oxyde, l'hydroxyde ou le carbonate de magnésium, le carbonate, le phosphate ou le citrate d'aluminium, de calcium, de sodium ou de potassium, les composés composites à l'aluminium/magnésium $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$ ou $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$, où n n'est pas un entier et est inférieur à deux.

45 6. Véhicule d'administration amélioré selon la revendication 4, dans lequel le cœur alcalin comprend un sel alcalin de l'omeprazole, tel que le sel de sodium, de potassium, de magnésium, de calcium ou d'ammonium.

50 7. Véhicule d'administration amélioré selon la revendication 4, dans lequel le cœur alcalin comprend un sel alcalin de l'omeprazole mélangé avec un composé autrement alcalin.

55 8. Véhicule d'administration amélioré selon la revendication 1, dans lequel l'enrobage externe entérique comprend du phtalate d'hydroxypropylméthylcellulose, de l'acétate-phtalate de cellulose, de l'acide méthacrylique/ester méthylique d'acide méthacrylique copolymérisé ou de l'acétate-phtalate de polyvinyle, contenant éventuellement un plastifiant.

60 9. Véhicule d'administration amélioré selon la revendication 1, qui présente une teneur en eau ne dépassant pas 1,5% en poids.